Salud financiera de hoja de balance de Akoya Biosciences

Salud financiera controles de criterios 4/6

Akoya Biosciences tiene un patrimonio de los accionistas total de $53.8M y una deuda total de $75.3M, lo que sitúa su ratio deuda-patrimonio en 140%. Sus activos y pasivos totales son $180.4M y $126.6M respectivamente.

Información clave

140.0%

Ratio deuda-patrimonio

US$75.25m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$83.13m
Patrimonio	US$53.77m
Total pasivo	US$126.60m
Activos totales	US$180.37m

Actualizaciones recientes sobre salud financiera

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Feb 28

Recent updates

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Feb 28

Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Nov 25

Akoya Biosciences Seeks Growth Despite Higher Operating Losses

May 30

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11

Akoya Biosciences and AstraZeneca ink collaboration agreement

Jun 04

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($121.8M) de AKYA superan a sus pasivos a corto plazo ($35.3M).

Pasivo a largo plazo: Los activos a corto plazo de AKYA ($121.8M) superan a sus pasivos a largo plazo ($91.3M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: AKYA tiene más efectivo que su deuda total.

Reducción de la deuda: No se dispone de datos suficientes para determinar si el ratio deuda-patrimonio de AKYA se ha reducido en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: AKYA tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si AKYA tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de Akoya Biosciences

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Recent updates

Akoya Biosciences, Inc., Annual General Meeting, Jun 04, 2024

Akoya Biosciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions At AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale

Consensus EPS estimates upgraded to US$0.83 loss

Full year 2023 earnings: EPS exceeds analyst expectations

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Akoya Biosciences, Inc. to Report Q4, 2023 Results on Mar 04, 2024

High number of new directors

Akoya Biosciences Deploys the Maxfuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory At Stanford University for Multiomic Integration of Spatial and Single-Cell Data on the Enable Medicine Platform

Akoya Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 and for the Fiscal Year 2024

Price target decreased by 11% to US$9.25

Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Consensus EPS estimates upgraded to US$1.46 loss

New minor risk - Share price stability

Price target decreased by 8.3% to US$11.00

Akoya Biosciences, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023

Price target decreased by 7.1% to US$13.13

Akoya Biosciences, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Akoya Biosciences, Inc. Launches PhenoCycler-Fusion 2.0 and Phenoimager HT 2.0 Platform Upgrades

Chief Operating Officer recently bought US$92k worth of stock

Akoya Biosciences, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Price target decreased by 12% to US$14.14

Akoya Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Price target decreased by 8.6% to US$16.00

New minor risk - Share price stability

Akoya Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $43.5 million.

Akoya Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $43.5 million.

Akoya Biosciences, Inc. Announces Executive Changes

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2023

Price target decreased by 7.9% to US$17.50

Consensus EPS estimates fall by 11%, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

Akoya Biosciences, Inc. to Report Q4, 2022 Results on Mar 06, 2023

Akoya Biosciences, Inc. to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting

Akoya Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Fiscal Year 2022

Chief Financial Officer exercised options to buy US$2.2m worth of stock.

Chief Financial Officer exercised options and sold US$298k worth of stock

President exercised options and sold US$59k worth of stock

Co-Founder recently sold US$67k worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder recently sold US$325k worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Akoya Biosciences, Inc Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy

Akoya Biosciences, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Co-Founder recently sold US$319k worth of stock

President exercised options and sold US$63k worth of stock

Price target increased to US$20.40

Consensus forecasts updated

Akoya Biosciences, Inc. Raises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Akoya Biosciences, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Price target decreased to US$18.60

President notifies of intention to sell stock

Akoya Biosciences Seeks Growth Despite Higher Operating Losses

Consensus forecasts updated

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Akoya Biosciences, Inc. Revises Revenue Guidance for the Full Year of 2022

Price target decreased to US$20.50

Akoya Biosciences, Inc., Annual General Meeting, Jun 01, 2022

Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer

Chief Business Officer exercised options to buy US$844k worth of stock.

Akoya Biosciences, Inc. to Report Q1, 2022 Results on May 05, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Akoya Biosciences, Inc. to Report Q4, 2021 Results on Mar 14, 2022

Akoya Biosciences Announces Commercial Launch of PhenoCycler-Fusion, the Faster Single-Cell Spatial Biology System

Akoya Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Consensus forecasts updated

Akoya Biosciences, Inc. Unveils Comprehensive Roadmap of Innovations at Inaugural Spatial Day Event

Co-Founder recently sold US$317k worth of stock